{"ticker": {"uuid": "05bd6bb7-0564-4cfe-bdd4-6fe01e44a148", "symbol": "ADXN", "name": "Addex Therapeutics Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How Addex Therapeutics Ltd (ADXN) Affects Rotational Strategy Timing", "summary": "Addex Therapeutics Ltd (ADXN) is showing strong near-term sentiment that could challenge current mid and long-term weakness. The article highlights an exceptional 69.5:1 risk-reward setup, targeting a 22.1% gain versus a 0.3% risk. AI models have generated three trading strategie", "url": "https://news.stocktradersdaily.com/news_release/17/How_Addex_Therapeutics_Ltd_ADXN_Affects_Rotational_Strategy_Timing_071226085202_1783860722.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T08:52:00", "published_display": "12 Jul 2026 08:52", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Announces Publication of Research Highlight Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness", "summary": "Addex Therapeutics announced the publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator of mGlu7, significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models. The study, published in the ", "url": "https://finance.yahoo.com/healthcare/articles/addex-announces-publication-research-highlighting-050000988.html", "source_name": "Market source", "published_at": "2026-07-08T23:06:05", "published_display": "08 Jul 2026 23:06", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Addex Announces Publication of Research Highlighting Therapeutic Potential of MGlu7 Modulation in Regulating Sleep and Wakefulness", "summary": "Addex announced the publication of research in the British Journal of Pharmacology highlighting the therapeutic potential of mGlu7 modulation in regulating sleep and wakefulness. The research, conducted in collaboration with research institutes in Germany and France, identified a", "url": "https://www.moomoo.com/news/post/72624985/press-release-addex-announces-publication-of-research-highlighting-therapeutic-potential", "source_name": "Moomoo", "published_at": "2026-07-08T11:40:26", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "mGlu7 sleep-wake study featured in Addex Therapeutics (ADXN) Form 6-K filing", "summary": "Addex Therapeutics announced new preclinical research on ADX71743, an mGlu7 negative allosteric modulator, demonstrating its significant role in modulating sleep-wake regulation and stress-related neurochemistry in animal models. The findings, published in the International Journ", "url": "https://www.stocktitan.net/sec-filings/ADXN/6-k-addex-therapeutics-ltd-current-report-foreign-issuer-54fcdcc6a694.html", "source_name": "Stock Titan", "published_at": "2026-07-08T10:10:44", "published_display": "08 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics (ADXN) Reveals Promising Preclinical Results on Sleep-Wake Regulation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AJBVV95cUxQNl9sR1N4WGdRYy1XRFJwX2UwWmVwZzk2UnhPSTNybVMxRnY1aVRVMGhZdTlZTTZFMXJGUVpKaWthaDY0WGFsenVXZDRRNTJCMF9QcjdpTjBSdzYzMHI1aUVrV3JIYVJ4SVRnTlphRnBDN1ZQVGxjNTIxZl8zVTlfX2hScU9nNnRRTXZoQi1ZTWhacnQ3M0FJaXdNbXVVcDh0NlktVXd0Um54VkJseVhtXzYzNFc5akVTQTdTRTM0Si1HWmw5WDY5OHE3ZVRpczE0cm1STlNvc1hqOHYwM0p4T0VNeExpUkQwQlRVR2Y4QWFrMzhGX3dLQ1hsUmRjTWdkam1rMkRfZU1mN25IQXUtVTU1Um1PQjVhc2hzRUlKTXduWlFvZXNKM2VsSHpNXzBhZEZUbVByeXYteVJrMmR1TUhqRFhrSk9yc2dLMGhVdXhnYzhDRmtsUUpyZjNsSTAyeVJXYg?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness", "summary": "Addex Therapeutics announced the publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator of metabotropic glutamate receptor 7 (mGlu7), significantly impacts sleep-wake regulation and stress-related neurochemistry in animal mo", "url": "https://www.manilatimes.net/2026/07/08/tmt-newswire/globenewswire/addex-announces-publication-of-research-highlighting-therapeutic-potential-of-mglu7-modulation-in-regulating-sleep-and-wakefulness/2380500/amp", "source_name": "The Manila Times", "published_at": "2026-07-08T06:10:44", "published_display": "08 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Addex Therapeutics Ltd \u2013 FWB:APE", "summary": "The article focuses on the \"Price to earnings forward\" metric for Addex Therapeutics Ltd (FWB: APE) on the Frankfurt Stock Exchange. It indicates that the market is closed and no trades have occurred for this specific financial data point during the period specified. The content ", "url": "https://www.tradingview.com/symbols/FWB-APE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T21:11:27", "published_display": "05 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(ADXN) and the Role of Price-Sensitive Allocations", "summary": "This article analyzes Addex Therapeutics Ltd (NASDAQ: ADXN), highlighting weak sentiment across all horizons and suggesting a short bias. It details institutional trading strategies, including long, breakout, and short positions with specific entry, target, and stop-loss zones. T", "url": "https://news.stocktradersdaily.com/news_release/21/ADXN_and_the_Role_of_Price-Sensitive_Allocations_070126074401_1782906241.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-01T07:39:49", "published_display": "01 Jul 2026 07:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics (ADXN) shareholders approve all AGM items and board slate", "summary": "Addex Therapeutics shareholders approved all Board of Directors' proposals at the 2026 Annual General Meeting, with votes representing 29.35% of the company\u2019s outstanding capital. This included approval of the 2025 annual report, financial statements, compensation report, and com", "url": "https://www.stocktitan.net/sec-filings/ADXN/6-k-addex-therapeutics-ltd-current-report-foreign-issuer-0690b0837904.html", "source_name": "Stock Titan", "published_at": "2026-06-30T10:09:55", "published_display": "30 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Shareholders Approve All Resolutions at Annual General Meeting", "summary": "Addex Therapeutics shareholders approved all Board of Directors' proposals at the 2026 Annual General Meeting, with 29.35% of outstanding capital represented. Key resolutions included approving financial statements, compensation reports, and re-electing board members and auditors", "url": "https://finance.yahoo.com/healthcare/articles/addex-shareholders-approve-resolutions-annual-050000925.html", "source_name": "Market source", "published_at": "2026-06-30T05:09:28", "published_display": "30 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Addex Therapeutics Ltd Sponsored ADR \u2013 LSX:A3EXC6", "summary": "This article provides financial information for Addex Therapeutics Ltd Sponsored ADR (LSX:A3EXC6), focusing on its price-to-earnings forward metric. The content appears to be a stub or an incomplete financial data page from TradingView, lacking specific numerical values for the m", "url": "https://www.tradingview.com/symbols/LSX-A3EXC6/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T18:50:04", "published_display": "26 Jun 2026 18:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Addex Therapeutics Ltd Sponsored ADR \u2013 LSX:A3EXC6", "summary": "The article focuses on the \"Enterprise value to revenue forward\" financial metric for Addex Therapeutics Ltd Sponsored ADR (LSX:A3EXC6). It presents this data from TradingView's financial overview for the company. The content appears to be a stub or a section of a larger financia", "url": "https://www.tradingview.com/symbols/LSX-A3EXC6/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:09:43", "published_display": "26 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:ADXN)", "summary": "The article provides a basic overview of Addex Therapeutics Ltd (NASDAQ:ADXN) on TradingView, focusing on its financial actuals and estimates. It highlights where users can explore reported financial data and analyst estimates across various financial statements and valuation met", "url": "https://www.tradingview.com/symbols/NASDAQ-ADXN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:09:43", "published_display": "26 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 2026 Addex Therapeutics Ltd Earnings Call Transcript", "summary": "Addex Therapeutics (ADXN) held its Q1 2026 earnings call, detailing progress in its GABAB positive modulator program for chronic cough and repositioning dipraglurant for brain injury recovery. Despite a low cash burn rate and a strong patent position for dipraglurant, the company", "url": "https://www.gurufocus.com/stock/ADXN/transcripts/8932313", "source_name": "GuruFocus", "published_at": "2026-06-26T07:10:02", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics Ltd Actuals & Estimates (SIX:ADXN)", "summary": "This article provides an overview of Addex Therapeutics Ltd (SIX:ADXN) stock performance, financial actuals, and estimates. It covers current stock price, market capitalization, volatility, historical highs and lows, and upcoming earnings reports, noting that ADXN stock has seen ", "url": "https://www.tradingview.com/symbols/SIX-ADXN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:52", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Addex Therapeutics Ltd Sponsored ADR \u2013 LSX:A3EXC6", "summary": "This article provides financial data for Addex Therapeutics Ltd Sponsored ADR (LSX:A3EXC6), specifically focusing on its forward price to sales ratio. The data presented is provided by FactSet Research Systems Inc. and is accessible through TradingView.", "url": "https://www.tradingview.com/symbols/LSX-A3EXC6/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:42:30", "published_display": "26 Jun 2026 02:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/addex-therapeutics-ltd-adxn-q1-210029222.html", "source_name": "GuruFocus.com", "published_at": "2026-06-25T21:00:29+00:00", "published_display": "25 Jun 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "Addex Therapeutics has announced its financial results for the first quarter of 2026. The press release provides a corporate update alongside the financial disclosures, indicating recent developments and future outlooks for the company.", "url": "https://www.moomoo.com/hans/news/post/72008459/press-release-addex-therapeutics-reports-first-quarter-2026-financial-results", "source_name": "Moomoo", "published_at": "2026-06-25T20:39:49", "published_display": "25 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics Q1 2026 Earnings Call Transcript", "summary": "Addex Therapeutics discussed its Q1 2026 results, highlighting robust preclinical data for its GABAB positive modulator in chronic cough and the repositioning of Dipraglurant for brain injury recovery. The company reported CHF 0.9 million in cash, supported by a small Q2 capital ", "url": "https://www.marketbeat.com/earnings/reports/2026-6-25-addex-therapeutics-ltd-stock/", "source_name": "MarketBeat", "published_at": "2026-06-25T19:10:27", "published_display": "25 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Addex Therapeutics trims loss in Q1 2026 as cash burn stays low", "summary": "Addex Therapeutics reported a narrower operating loss of CHF 0.5 million in Q1 2026, aided by reduced outsourced R&D spending, which extends its cash runway into Q4 2026. The net loss, however, widened to CHF 1.7 million due to its equity share in Neurosterix's advancing programs", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-addex-therapeutics-trims-loss-in-q1-2026-as-cash-burn-stays-low-93CH-4761036", "source_name": "Investing.com", "published_at": "2026-06-25T16:42:30", "published_display": "25 Jun 2026 16:42", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript", "summary": "Addex Therapeutics reported its Q1 2026 financial results and provided a corporate update, highlighting significant progress in its GABAB Positive Modulator Cough program and the repositioning of Diproglurant for brain injury recovery. The company reported an operating loss of 0.", "url": "https://www.benzinga.com/news/26/06/60102662/addex-therapeutics-reports-q1-2026-results-full-earnings-call-transcript", "source_name": "Benzinga", "published_at": "2026-06-25T14:40:56", "published_display": "25 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics Releases Q1 2026 Financial Results", "summary": "Addex Therapeutics reported a Q1 2026 net loss of CHF 1.7M, an increase from the previous year, with a basic and diluted net loss per share of CHF 0.01, which remained unchanged year-over-year. Despite reducing quarterly losses, analyst sentiment remains cautious, with a consensu", "url": "https://news.alphastreet.com/addex-therapeutics-releases-q1-2026-financial-results/amp/", "source_name": "AlphaStreet", "published_at": "2026-06-25T10:40:56", "published_display": "25 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics (ADXN) posts Q1 loss and flags going-concern risk", "summary": "Addex Therapeutics reported a Q1 2026 net loss of CHF 1.71 million, with cash and cash equivalents falling to CHF 0.94 million. The company's cash runway is projected only through July 2026, leading to a formal \"going concern\" warning due to substantial doubt about its ability to", "url": "https://www.stocktitan.net/sec-filings/ADXN/6-k-addex-therapeutics-ltd-current-report-foreign-issuer-bb646da1da9b.html", "source_name": "Stock Titan", "published_at": "2026-06-25T09:40:56", "published_display": "25 Jun 2026 09:40", "sentiment": "negative", "sentiment_pct": 20, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics narrows Q1 loss, advances GABAB program", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPXzdobTBPLVV1ZUZIR0dCYWNzOGlFWC1NU1JFLTNHTTZvS1J0c2U2Z1Y3WnFlNTl1bGRjM3NpMHJYd2pKeHBoQWJaUkFxOVI0VFhWZEVBT29JTDRSb1RzbnlQRHZQYjlQR2pjTS04RXlEb181d3NSTHB5LXJ6eU00VERPR25teG1JbkEwdjJuUHBVUEtSTVlJV04yV3lJWDd3bGpxVkNoN1FQbHF1UGhLNVRxQ1lkZ3ZzTVQ3MEJuNA?oc=5", "source_name": "scanx.trade", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "Addex Therapeutics reported its Q1 2026 financial results, highlighting progress in its spin-out Neurosterix's Phase 1 study for NTX-253 and continued preclinical development of a GABAB PAM chronic cough candidate. The company recorded a net loss of CHF 1.7 million for the period", "url": "https://uk.finance.yahoo.com/news/addex-therapeutics-reports-first-quarter-050000143.html", "source_name": "Market source", "published_at": "2026-06-25T07:10:02", "published_display": "25 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADXN: Net loss widened to CHF 1.7 million as clinical programs advanced and cash reserves declined", "summary": "Addex Therapeutics (ADXN) reported a widened net loss of CHF 1.7 million in Q1 2026, with cash reserves decreasing to CHF 0.9 million. This occurred despite reduced income and expenses, as the company advanced its clinical pipeline, notably with Neurosterix's Phase 1 schizophreni", "url": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3649672:0-adxn-net-loss-widened-to-chf-1-7-million-as-clinical-programs-advanced-and-cash-reserves-declined/", "source_name": "TradingView", "published_at": "2026-06-25T05:40:56", "published_display": "25 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 20, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026", "summary": "Addex Therapeutics is scheduled to report its 2026 First Quarter financial results and host a conference call on June 25, 2026. Separately, Unity Software (U.US) reported its Q4 earnings with revenue increasing 35% year-over-year to $609 million, though it posted a quarterly loss", "url": "https://www.moomoo.com/news/post/71801913/press-release-addex-therapeutics-to-report-2026-first-quarter-financial?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-22T16:40:44", "published_display": "22 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics to Report 2026 First Quarter Financial Results  and Host Conference Call on June 25, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/addex-therapeutics-report-2026-first-050000979.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T05:00:00+00:00", "published_display": "22 Jun 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics to report Q1 2026 financial results on June 25", "summary": "Addex Therapeutics announced it will report its First Quarter 2026 financial results on June 25, 2026, followed by a webcast and teleconference. CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev will lead the presentation, discussing the financial results and prov", "url": "https://scanx.trade/stock-market-news/companies/addex-therapeutics-to-report-q1-2026-financial-results-on-june-25/43650452", "source_name": "scanx.trade", "published_at": "2026-06-21T16:12:29", "published_display": "21 Jun 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the ADXN Inflection", "summary": "Addex Therapeutics Ltd (NASDAQ: ADXN) is showing weak sentiment across all horizons, supporting a short bias, with an \"exceptional 54.5:1 risk-reward short setup.\" AI models have generated three trading strategies: a position trading strategy, a momentum breakout strategy, and a ", "url": "https://news.stocktradersdaily.com/news_release/22/Responsive_Playbooks_and_the_ADXN_Inflection_062026063201_1781951521.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-20T06:39:59", "published_display": "20 Jun 2026 06:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics (ADXN) Holds Steady \u2013 Consolidation Near Support May Signal Next Move - Force Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNSXpQOUdSVEFlazF6aVBRUlg2LTJyWDg1Tk50UHZyTnhVdjlIdXFnOWVJU3pyYldHd3AyLVZVVlFySkkxOWxTRnRyam8zcFpsQVdVZkVOQXpOYXhHUHc0Z0Zmc0w0QlljWDVqVElreWkyYXhwRUd6bkJaTnh0Zjk5eTZXWHo1aUM2TWo1NU5LUUJfRy1NQjBfZk1QRFgyZDMyRm1HcTJQNVNaME93N2VWcHFWOVpQd292UWNxWExqUFY4WC1VMHN5dWN1ZWY?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Convenes Annual General Meeting 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/addex-convenes-annual-general-meeting-050000629.html", "source_name": "GlobeNewswire", "published_at": "2026-06-05T05:00:00+00:00", "published_display": "05 Jun 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics Q1 2024 Earnings: Continued R&D Spending Weighs on Bottom Line as Pipeline Progresses - One-Time Gain Impact", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNTmJhaEZtTXAtei1kRFh4NkhpWnhwcWluZ0xuVWFpZEQxSjFCSjN6LUU4REFoc1M4WEduUnJEcVllU3ZsM3prdnRIeDJybUpObmd1TUtOSkhUcWVIMUFoMTJrVy1YdmJKZ2xtSUoxZzc2RjBVWGNHbnRoSzU0SjNNa2d6V1VRUU1tZE9qVVVoa2xZR2ZzTE5BdUpRckJwMUZVQTJnZno4RlgyQ3pBdzgzOWpHdlhJd0dLamM3T29DWC12WC16RDBKNFFYcFhBazlqckhENGtIeUlMR05sX2Fz?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics (ADXN) Drops 2.49%, Hovers Near Key Support at $6.32 - Intraday Profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQZzJMUFU0dnVGZ0h5OXduRXJlQmZZVy1Oel8wdFZhejk0c2VrdTVCeWdLNExZY0FVMnZDSEgtbldzenlqb2pNTERYOTdwYVAydXRiZTRGeFpGTFRMSWJJZC1LeEtEb2FIb0FwVmg1MUJyTUtmMVZ0RGxwVGY4ODU5OHIwT1dOZHBuT3Q1ZkZfdGFXaE43Z29JNWp1MnhORWhKeWxuVFdsNUFINzZI?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics (ADXN) Drops 2.49%, Hovers Near Key Support at $6.32 - Covered Call Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQbWVGYU9KNDQwZ3FFNzJRM0wwQlFnaU5fQnZwM0hnQnpHMEs3djZRdUJ5QVVEM21raFVXeXZFVS1MNU5qU0pxOElHdWxXSmFWNjg4M3pCbnpka21FZTdubjU3TGg5SGV0VDVRVUN0by01TXExZFY4ZEx1VlBjanFpZUlqUV9TMm55d0M5dVpSSnpIcUl1UXRacmFYMFBMQzhWOUNLY3ZOSmtFeUJTMUFTLQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Addex Therapeutics H2 2025 Earnings Call Transcript", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNRVl6eld3eWZHUVZBNmEyYkJVZ3ZQT3pLazNiQXRSdklwN1Y1RkROWkVGdkQzVHlHS2NHTWxMOFBCVWdhYzVZWWg1Nl96TmNMbnRDZ0FzdEVLYW5ReXZTVC1hNDJ1b3pGWU9abDNQNnRHNjJMeUFFQ0lRQVlJNjhQZjJGcUxuOGFsV1E?oc=5", "source_name": "MarketBeat", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Reports Full Year 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/addex-reports-full-2025-financial-050000465.html", "source_name": "GlobeNewswire", "published_at": "2026-04-30T05:00:00+00:00", "published_display": "30 Apr 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/addex-gabab-pam-candidate-demonstrates-050000599.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T05:00:00+00:00", "published_display": "29 Apr 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/addex-spin-company-neurosterix-track-050000726.html", "source_name": "GlobeNewswire", "published_at": "2026-04-23T05:00:00+00:00", "published_display": "23 Apr 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/addex-gabab-pam-candidate-demonstrates-050000394.html", "source_name": "GlobeNewswire", "published_at": "2026-04-21T05:00:00+00:00", "published_display": "21 Apr 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Addex Therapeutics (ADXN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5ON05SeVZfcHEzZmpfUTF4OXQ3Zm1JeXBOR2F6djVuY0dKRkhvWGNpMS15Y01TVW4ycENaNWJ3bC1la183ajFlR0N0Q0MzQ0RjaHVZ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T04:35:12+00:00", "published_display": "25 Apr 2025 04:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxPVWZQNGs3ajNob3ZSbTJ1bXIxQmdfWnZJVE9pVng3YnpzZ2kycnF2blJXM2c0dENpYnVzbW52SDcybVNMWFV2MU9PdF91Zk92dWNaalRocHNMMmdxU0RwWWFMX3VNdHpzbEVTZmlaZGdyRmpGNWZhYk9YcUo2R1B5QUNxeTdQTXlOYVNRVVJ0VWptZG1VaUxFS0NHWUs5N0piR2dOMm5uSE44YTBkYjJ6cjNMdWJzOW1rbTh5cWIwQnd1a0JBY0paOGc1MmtKSE9nVDZUUlJvUklzMldwVEhxQW1wWDUyR3dH?oc=5", "source_name": "GlobeNewswire", "published_at": "2024-01-31T08:00:00+00:00", "published_display": "31 Jan 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "How Addex Therapeutics Ltd (ADXN) Affects Rotational Strategy Timing", "summary": "Addex Therapeutics Ltd (ADXN) is showing strong near-term sentiment that could challenge current mid and long-term weakness. The article highlights an exceptional 69.5:1 risk-reward setup, targeting a 22.1% gain versus a 0.3% risk. AI models have generated three trading strategie", "url": "https://news.stocktradersdaily.com/news_release/17/How_Addex_Therapeutics_Ltd_ADXN_Affects_Rotational_Strategy_Timing_071226085202_1783860722.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T08:52:00", "published_display": "12 Jul 2026 08:52", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Announces Publication of Research Highlight Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness", "summary": "Addex Therapeutics announced the publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator of mGlu7, significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models. The study, published in the ", "url": "https://finance.yahoo.com/healthcare/articles/addex-announces-publication-research-highlighting-050000988.html", "source_name": "Market source", "published_at": "2026-07-08T23:06:05", "published_display": "08 Jul 2026 23:06", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Addex Announces Publication of Research Highlighting Therapeutic Potential of MGlu7 Modulation in Regulating Sleep and Wakefulness", "summary": "Addex announced the publication of research in the British Journal of Pharmacology highlighting the therapeutic potential of mGlu7 modulation in regulating sleep and wakefulness. The research, conducted in collaboration with research institutes in Germany and France, identified a", "url": "https://www.moomoo.com/news/post/72624985/press-release-addex-announces-publication-of-research-highlighting-therapeutic-potential", "source_name": "Moomoo", "published_at": "2026-07-08T11:40:26", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "mGlu7 sleep-wake study featured in Addex Therapeutics (ADXN) Form 6-K filing", "summary": "Addex Therapeutics announced new preclinical research on ADX71743, an mGlu7 negative allosteric modulator, demonstrating its significant role in modulating sleep-wake regulation and stress-related neurochemistry in animal models. The findings, published in the International Journ", "url": "https://www.stocktitan.net/sec-filings/ADXN/6-k-addex-therapeutics-ltd-current-report-foreign-issuer-54fcdcc6a694.html", "source_name": "Stock Titan", "published_at": "2026-07-08T10:10:44", "published_display": "08 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics (ADXN) Reveals Promising Preclinical Results on Sleep-Wake Regulation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AJBVV95cUxQNl9sR1N4WGdRYy1XRFJwX2UwWmVwZzk2UnhPSTNybVMxRnY1aVRVMGhZdTlZTTZFMXJGUVpKaWthaDY0WGFsenVXZDRRNTJCMF9QcjdpTjBSdzYzMHI1aUVrV3JIYVJ4SVRnTlphRnBDN1ZQVGxjNTIxZl8zVTlfX2hScU9nNnRRTXZoQi1ZTWhacnQ3M0FJaXdNbXVVcDh0NlktVXd0Um54VkJseVhtXzYzNFc5akVTQTdTRTM0Si1HWmw5WDY5OHE3ZVRpczE0cm1STlNvc1hqOHYwM0p4T0VNeExpUkQwQlRVR2Y4QWFrMzhGX3dLQ1hsUmRjTWdkam1rMkRfZU1mN25IQXUtVTU1Um1PQjVhc2hzRUlKTXduWlFvZXNKM2VsSHpNXzBhZEZUbVByeXYteVJrMmR1TUhqRFhrSk9yc2dLMGhVdXhnYzhDRmtsUUpyZjNsSTAyeVJXYg?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness", "summary": "Addex Therapeutics announced the publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator of metabotropic glutamate receptor 7 (mGlu7), significantly impacts sleep-wake regulation and stress-related neurochemistry in animal mo", "url": "https://www.manilatimes.net/2026/07/08/tmt-newswire/globenewswire/addex-announces-publication-of-research-highlighting-therapeutic-potential-of-mglu7-modulation-in-regulating-sleep-and-wakefulness/2380500/amp", "source_name": "The Manila Times", "published_at": "2026-07-08T06:10:44", "published_display": "08 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Addex Therapeutics Ltd \u2013 FWB:APE", "summary": "The article focuses on the \"Price to earnings forward\" metric for Addex Therapeutics Ltd (FWB: APE) on the Frankfurt Stock Exchange. It indicates that the market is closed and no trades have occurred for this specific financial data point during the period specified. The content ", "url": "https://www.tradingview.com/symbols/FWB-APE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T21:11:27", "published_display": "05 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(ADXN) and the Role of Price-Sensitive Allocations", "summary": "This article analyzes Addex Therapeutics Ltd (NASDAQ: ADXN), highlighting weak sentiment across all horizons and suggesting a short bias. It details institutional trading strategies, including long, breakout, and short positions with specific entry, target, and stop-loss zones. T", "url": "https://news.stocktradersdaily.com/news_release/21/ADXN_and_the_Role_of_Price-Sensitive_Allocations_070126074401_1782906241.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-01T07:39:49", "published_display": "01 Jul 2026 07:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics (ADXN) shareholders approve all AGM items and board slate", "summary": "Addex Therapeutics shareholders approved all Board of Directors' proposals at the 2026 Annual General Meeting, with votes representing 29.35% of the company\u2019s outstanding capital. This included approval of the 2025 annual report, financial statements, compensation report, and com", "url": "https://www.stocktitan.net/sec-filings/ADXN/6-k-addex-therapeutics-ltd-current-report-foreign-issuer-0690b0837904.html", "source_name": "Stock Titan", "published_at": "2026-06-30T10:09:55", "published_display": "30 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Shareholders Approve All Resolutions at Annual General Meeting", "summary": "Addex Therapeutics shareholders approved all Board of Directors' proposals at the 2026 Annual General Meeting, with 29.35% of outstanding capital represented. Key resolutions included approving financial statements, compensation reports, and re-electing board members and auditors", "url": "https://finance.yahoo.com/healthcare/articles/addex-shareholders-approve-resolutions-annual-050000925.html", "source_name": "Market source", "published_at": "2026-06-30T05:09:28", "published_display": "30 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Addex Therapeutics Ltd Sponsored ADR \u2013 LSX:A3EXC6", "summary": "This article provides financial information for Addex Therapeutics Ltd Sponsored ADR (LSX:A3EXC6), focusing on its price-to-earnings forward metric. The content appears to be a stub or an incomplete financial data page from TradingView, lacking specific numerical values for the m", "url": "https://www.tradingview.com/symbols/LSX-A3EXC6/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T18:50:04", "published_display": "26 Jun 2026 18:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Addex Therapeutics Ltd Sponsored ADR \u2013 LSX:A3EXC6", "summary": "The article focuses on the \"Enterprise value to revenue forward\" financial metric for Addex Therapeutics Ltd Sponsored ADR (LSX:A3EXC6). It presents this data from TradingView's financial overview for the company. The content appears to be a stub or a section of a larger financia", "url": "https://www.tradingview.com/symbols/LSX-A3EXC6/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:09:43", "published_display": "26 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:ADXN)", "summary": "The article provides a basic overview of Addex Therapeutics Ltd (NASDAQ:ADXN) on TradingView, focusing on its financial actuals and estimates. It highlights where users can explore reported financial data and analyst estimates across various financial statements and valuation met", "url": "https://www.tradingview.com/symbols/NASDAQ-ADXN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:09:43", "published_display": "26 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 2026 Addex Therapeutics Ltd Earnings Call Transcript", "summary": "Addex Therapeutics (ADXN) held its Q1 2026 earnings call, detailing progress in its GABAB positive modulator program for chronic cough and repositioning dipraglurant for brain injury recovery. Despite a low cash burn rate and a strong patent position for dipraglurant, the company", "url": "https://www.gurufocus.com/stock/ADXN/transcripts/8932313", "source_name": "GuruFocus", "published_at": "2026-06-26T07:10:02", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics Ltd Actuals & Estimates (SIX:ADXN)", "summary": "This article provides an overview of Addex Therapeutics Ltd (SIX:ADXN) stock performance, financial actuals, and estimates. It covers current stock price, market capitalization, volatility, historical highs and lows, and upcoming earnings reports, noting that ADXN stock has seen ", "url": "https://www.tradingview.com/symbols/SIX-ADXN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:52", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Addex Therapeutics Ltd Sponsored ADR \u2013 LSX:A3EXC6", "summary": "This article provides financial data for Addex Therapeutics Ltd Sponsored ADR (LSX:A3EXC6), specifically focusing on its forward price to sales ratio. The data presented is provided by FactSet Research Systems Inc. and is accessible through TradingView.", "url": "https://www.tradingview.com/symbols/LSX-A3EXC6/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:42:30", "published_display": "26 Jun 2026 02:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/addex-therapeutics-ltd-adxn-q1-210029222.html", "source_name": "GuruFocus.com", "published_at": "2026-06-25T21:00:29+00:00", "published_display": "25 Jun 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "Addex Therapeutics has announced its financial results for the first quarter of 2026. The press release provides a corporate update alongside the financial disclosures, indicating recent developments and future outlooks for the company.", "url": "https://www.moomoo.com/hans/news/post/72008459/press-release-addex-therapeutics-reports-first-quarter-2026-financial-results", "source_name": "Moomoo", "published_at": "2026-06-25T20:39:49", "published_display": "25 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics Q1 2026 Earnings Call Transcript", "summary": "Addex Therapeutics discussed its Q1 2026 results, highlighting robust preclinical data for its GABAB positive modulator in chronic cough and the repositioning of Dipraglurant for brain injury recovery. The company reported CHF 0.9 million in cash, supported by a small Q2 capital ", "url": "https://www.marketbeat.com/earnings/reports/2026-6-25-addex-therapeutics-ltd-stock/", "source_name": "MarketBeat", "published_at": "2026-06-25T19:10:27", "published_display": "25 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Addex Therapeutics trims loss in Q1 2026 as cash burn stays low", "summary": "Addex Therapeutics reported a narrower operating loss of CHF 0.5 million in Q1 2026, aided by reduced outsourced R&D spending, which extends its cash runway into Q4 2026. The net loss, however, widened to CHF 1.7 million due to its equity share in Neurosterix's advancing programs", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-addex-therapeutics-trims-loss-in-q1-2026-as-cash-burn-stays-low-93CH-4761036", "source_name": "Investing.com", "published_at": "2026-06-25T16:42:30", "published_display": "25 Jun 2026 16:42", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript", "summary": "Addex Therapeutics reported its Q1 2026 financial results and provided a corporate update, highlighting significant progress in its GABAB Positive Modulator Cough program and the repositioning of Diproglurant for brain injury recovery. The company reported an operating loss of 0.", "url": "https://www.benzinga.com/news/26/06/60102662/addex-therapeutics-reports-q1-2026-results-full-earnings-call-transcript", "source_name": "Benzinga", "published_at": "2026-06-25T14:40:56", "published_display": "25 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics Releases Q1 2026 Financial Results", "summary": "Addex Therapeutics reported a Q1 2026 net loss of CHF 1.7M, an increase from the previous year, with a basic and diluted net loss per share of CHF 0.01, which remained unchanged year-over-year. Despite reducing quarterly losses, analyst sentiment remains cautious, with a consensu", "url": "https://news.alphastreet.com/addex-therapeutics-releases-q1-2026-financial-results/amp/", "source_name": "AlphaStreet", "published_at": "2026-06-25T10:40:56", "published_display": "25 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics (ADXN) posts Q1 loss and flags going-concern risk", "summary": "Addex Therapeutics reported a Q1 2026 net loss of CHF 1.71 million, with cash and cash equivalents falling to CHF 0.94 million. The company's cash runway is projected only through July 2026, leading to a formal \"going concern\" warning due to substantial doubt about its ability to", "url": "https://www.stocktitan.net/sec-filings/ADXN/6-k-addex-therapeutics-ltd-current-report-foreign-issuer-bb646da1da9b.html", "source_name": "Stock Titan", "published_at": "2026-06-25T09:40:56", "published_display": "25 Jun 2026 09:40", "sentiment": "negative", "sentiment_pct": 20, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics narrows Q1 loss, advances GABAB program", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPXzdobTBPLVV1ZUZIR0dCYWNzOGlFWC1NU1JFLTNHTTZvS1J0c2U2Z1Y3WnFlNTl1bGRjM3NpMHJYd2pKeHBoQWJaUkFxOVI0VFhWZEVBT29JTDRSb1RzbnlQRHZQYjlQR2pjTS04RXlEb181d3NSTHB5LXJ6eU00VERPR25teG1JbkEwdjJuUHBVUEtSTVlJV04yV3lJWDd3bGpxVkNoN1FQbHF1UGhLNVRxQ1lkZ3ZzTVQ3MEJuNA?oc=5", "source_name": "scanx.trade", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "Addex Therapeutics reported its Q1 2026 financial results, highlighting progress in its spin-out Neurosterix's Phase 1 study for NTX-253 and continued preclinical development of a GABAB PAM chronic cough candidate. The company recorded a net loss of CHF 1.7 million for the period", "url": "https://uk.finance.yahoo.com/news/addex-therapeutics-reports-first-quarter-050000143.html", "source_name": "Market source", "published_at": "2026-06-25T07:10:02", "published_display": "25 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADXN: Net loss widened to CHF 1.7 million as clinical programs advanced and cash reserves declined", "summary": "Addex Therapeutics (ADXN) reported a widened net loss of CHF 1.7 million in Q1 2026, with cash reserves decreasing to CHF 0.9 million. This occurred despite reduced income and expenses, as the company advanced its clinical pipeline, notably with Neurosterix's Phase 1 schizophreni", "url": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3649672:0-adxn-net-loss-widened-to-chf-1-7-million-as-clinical-programs-advanced-and-cash-reserves-declined/", "source_name": "TradingView", "published_at": "2026-06-25T05:40:56", "published_display": "25 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 20, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026", "summary": "Addex Therapeutics is scheduled to report its 2026 First Quarter financial results and host a conference call on June 25, 2026. Separately, Unity Software (U.US) reported its Q4 earnings with revenue increasing 35% year-over-year to $609 million, though it posted a quarterly loss", "url": "https://www.moomoo.com/news/post/71801913/press-release-addex-therapeutics-to-report-2026-first-quarter-financial?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-22T16:40:44", "published_display": "22 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics to Report 2026 First Quarter Financial Results  and Host Conference Call on June 25, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/addex-therapeutics-report-2026-first-050000979.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T05:00:00+00:00", "published_display": "22 Jun 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics to report Q1 2026 financial results on June 25", "summary": "Addex Therapeutics announced it will report its First Quarter 2026 financial results on June 25, 2026, followed by a webcast and teleconference. CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev will lead the presentation, discussing the financial results and prov", "url": "https://scanx.trade/stock-market-news/companies/addex-therapeutics-to-report-q1-2026-financial-results-on-june-25/43650452", "source_name": "scanx.trade", "published_at": "2026-06-21T16:12:29", "published_display": "21 Jun 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the ADXN Inflection", "summary": "Addex Therapeutics Ltd (NASDAQ: ADXN) is showing weak sentiment across all horizons, supporting a short bias, with an \"exceptional 54.5:1 risk-reward short setup.\" AI models have generated three trading strategies: a position trading strategy, a momentum breakout strategy, and a ", "url": "https://news.stocktradersdaily.com/news_release/22/Responsive_Playbooks_and_the_ADXN_Inflection_062026063201_1781951521.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-20T06:39:59", "published_display": "20 Jun 2026 06:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics (ADXN) Holds Steady \u2013 Consolidation Near Support May Signal Next Move - Force Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNSXpQOUdSVEFlazF6aVBRUlg2LTJyWDg1Tk50UHZyTnhVdjlIdXFnOWVJU3pyYldHd3AyLVZVVlFySkkxOWxTRnRyam8zcFpsQVdVZkVOQXpOYXhHUHc0Z0Zmc0w0QlljWDVqVElreWkyYXhwRUd6bkJaTnh0Zjk5eTZXWHo1aUM2TWo1NU5LUUJfRy1NQjBfZk1QRFgyZDMyRm1HcTJQNVNaME93N2VWcHFWOVpQd292UWNxWExqUFY4WC1VMHN5dWN1ZWY?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Convenes Annual General Meeting 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/addex-convenes-annual-general-meeting-050000629.html", "source_name": "GlobeNewswire", "published_at": "2026-06-05T05:00:00+00:00", "published_display": "05 Jun 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics Q1 2024 Earnings: Continued R&D Spending Weighs on Bottom Line as Pipeline Progresses - One-Time Gain Impact", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNTmJhaEZtTXAtei1kRFh4NkhpWnhwcWluZ0xuVWFpZEQxSjFCSjN6LUU4REFoc1M4WEduUnJEcVllU3ZsM3prdnRIeDJybUpObmd1TUtOSkhUcWVIMUFoMTJrVy1YdmJKZ2xtSUoxZzc2RjBVWGNHbnRoSzU0SjNNa2d6V1VRUU1tZE9qVVVoa2xZR2ZzTE5BdUpRckJwMUZVQTJnZno4RlgyQ3pBdzgzOWpHdlhJd0dLamM3T29DWC12WC16RDBKNFFYcFhBazlqckhENGtIeUlMR05sX2Fz?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics (ADXN) Drops 2.49%, Hovers Near Key Support at $6.32 - Intraday Profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQZzJMUFU0dnVGZ0h5OXduRXJlQmZZVy1Oel8wdFZhejk0c2VrdTVCeWdLNExZY0FVMnZDSEgtbldzenlqb2pNTERYOTdwYVAydXRiZTRGeFpGTFRMSWJJZC1LeEtEb2FIb0FwVmg1MUJyTUtmMVZ0RGxwVGY4ODU5OHIwT1dOZHBuT3Q1ZkZfdGFXaE43Z29JNWp1MnhORWhKeWxuVFdsNUFINzZI?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics (ADXN) Drops 2.49%, Hovers Near Key Support at $6.32 - Covered Call Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQbWVGYU9KNDQwZ3FFNzJRM0wwQlFnaU5fQnZwM0hnQnpHMEs3djZRdUJ5QVVEM21raFVXeXZFVS1MNU5qU0pxOElHdWxXSmFWNjg4M3pCbnpka21FZTdubjU3TGg5SGV0VDVRVUN0by01TXExZFY4ZEx1VlBjanFpZUlqUV9TMm55d0M5dVpSSnpIcUl1UXRacmFYMFBMQzhWOUNLY3ZOSmtFeUJTMUFTLQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics H2 2025 Earnings Call Transcript", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNRVl6eld3eWZHUVZBNmEyYkJVZ3ZQT3pLazNiQXRSdklwN1Y1RkROWkVGdkQzVHlHS2NHTWxMOFBCVWdhYzVZWWg1Nl96TmNMbnRDZ0FzdEVLYW5ReXZTVC1hNDJ1b3pGWU9abDNQNnRHNjJMeUFFQ0lRQVlJNjhQZjJGcUxuOGFsV1E?oc=5", "source_name": "MarketBeat", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Reports Full Year 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/addex-reports-full-2025-financial-050000465.html", "source_name": "GlobeNewswire", "published_at": "2026-04-30T05:00:00+00:00", "published_display": "30 Apr 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/addex-gabab-pam-candidate-demonstrates-050000599.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T05:00:00+00:00", "published_display": "29 Apr 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/addex-spin-company-neurosterix-track-050000726.html", "source_name": "GlobeNewswire", "published_at": "2026-04-23T05:00:00+00:00", "published_display": "23 Apr 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/addex-gabab-pam-candidate-demonstrates-050000394.html", "source_name": "GlobeNewswire", "published_at": "2026-04-21T05:00:00+00:00", "published_display": "21 Apr 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Therapeutics (ADXN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5ON05SeVZfcHEzZmpfUTF4OXQ3Zm1JeXBOR2F6djVuY0dKRkhvWGNpMS15Y01TVW4ycENaNWJ3bC1la183ajFlR0N0Q0MzQ0RjaHVZ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T04:35:12+00:00", "published_display": "25 Apr 2025 04:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxPVWZQNGs3ajNob3ZSbTJ1bXIxQmdfWnZJVE9pVng3YnpzZ2kycnF2blJXM2c0dENpYnVzbW52SDcybVNMWFV2MU9PdF91Zk92dWNaalRocHNMMmdxU0RwWWFMX3VNdHpzbEVTZmlaZGdyRmpGNWZhYk9YcUo2R1B5QUNxeTdQTXlOYVNRVVJ0VWptZG1VaUxFS0NHWUs5N0piR2dOMm5uSE44YTBkYjJ6cjNMdWJzOW1rbTh5cWIwQnd1a0JBY0paOGc1MmtKSE9nVDZUUlJvUklzMldwVEhxQW1wWDUyR3dH?oc=5", "source_name": "GlobeNewswire", "published_at": "2024-01-31T08:00:00+00:00", "published_display": "31 Jan 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 50, "sentiment_summary": {"positive": 12, "negative": 7, "neutral": 31, "score": 51, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 77, "events": [{"event": "earnings", "label": "Earnings", "weight": 12.65, "count": 25}, {"event": "general", "label": "Market update", "weight": 9.9, "count": 18}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 6.34, "latest_week": "2026-07-10", "one_week_move": 9.5, "four_week_move": -1.7, "twelve_week_move": -5.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.071322, "market_dynamics_buy_signal": false, "relative_strength": -29.801893, "fair_value_gap": -26.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.2008, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+9.5% over one week, -1.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "TradingView", "count": 8}, {"label": "GlobeNewswire", "count": 7}, {"label": "Stock Titan", "count": 4}, {"label": "Stock Traders Daily", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "GuruFocus", "count": 2}, {"label": "MarketBeat", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 25}, {"label": "Market update", "count": 18}, {"label": "Balance sheet", "count": 4}, {"label": "Analyst action", "count": 2}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+9.5% over one week, -1.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "How Addex Therapeutics Ltd (ADXN) Affects Rotational Strategy Timing"}], "updated_at": "2026-07-16T04:33:52.727560+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}